1,32 €
Deine Einschätzung
Marinus Pharmaceuticals Inc. Aktie
Marinus Pharmaceuticals Inc. ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Therapeutika für seltene neurologische Erkrankungen konzentriert. Das Unternehmen konzentriert sich auf die klinische Entwicklung von ganaxolon, einem Arzneimittelkandidaten zur Behandlung von schweren epileptischen Erkrankungen wie dem Lennox-Gastaut-Syndrom und dem CDKL5-Mangel-Syndrom. Marinus Pharmaceuticals Inc. ist an der NASDAQ-Börse gelistet und hat seinen Hauptsitz in New Jersey, USA.
Was spricht für und gegen Marinus Pharmaceuticals Inc. in den nächsten Jahren?
Pro
Kontra
Kommentare
News
![Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder: https://mms.businesswire.com/media/20240405633110/en/2090706/5/marinus-color-R.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMnRzYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--76e52eaed59bc59bb8fe57245d18d05a1a7af0d8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/marinus-color-R.jpg?locale=de)
Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National
![Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program: https://mms.businesswire.com/media/20240405633110/en/2090706/5/marinus-color-R.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMnRzYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--76e52eaed59bc59bb8fe57245d18d05a1a7af0d8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/marinus-color-R.jpg?locale=de)
Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced completion of enrollment in
![Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results: https://mms.businesswire.com/media/20240405633110/en/2090706/5/marinus-color-R.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMnRzYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--76e52eaed59bc59bb8fe57245d18d05a1a7af0d8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/marinus-color-R.jpg?locale=de)
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and